Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CPT Pharmacometrics Syst Pharmacol
Main Authors: Zhang, Jason, Sanghavi, Kinjal, Shen, Jun, Zhao, Xiaochen, Feng, Yan, Statkevich, Paul, Sheng, Jennifer, Roy, Amit, Zhu, Li
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930858/
https://ncbi.nlm.nih.gov/pubmed/31710163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12476
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados